Literature DB >> 28263308

Autoimmunity against a defective ribosomal insulin gene product in type 1 diabetes.

Maria J L Kracht1,2, Menno van Lummel2, Tatjana Nikolic2, Antoinette M Joosten2, Sandra Laban2, Arno R van der Slik2, Peter A van Veelen3, Françoise Carlotti4, Eelco J P de Koning4, Rob C Hoeben1, Arnaud Zaldumbide1, Bart O Roep2,5.   

Abstract

Identification of epitopes that are recognized by diabetogenic T cells and cause selective beta cell destruction in type 1 diabetes (T1D) has focused on peptides originating from native beta cell proteins. Translational errors represent a major potential source of antigenic peptides to which central immune tolerance is lacking. Here, we describe an alternative open reading frame within human insulin mRNA encoding a highly immunogenic polypeptide that is targeted by T cells in T1D patients. We show that cytotoxic T cells directed against the N-terminal peptide of this nonconventional product are present in the circulation of individuals diagnosed with T1D, and we provide direct evidence that such CD8+ T cells are capable of killing human beta cells and thereby may be diabetogenic. This study reveals a new source of nonconventional polypeptides that act as self-epitopes in clinical autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28263308     DOI: 10.1038/nm.4289

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  84 in total

1.  T-cell responses to hybrid insulin peptides prior to type 1 diabetes development.

Authors:  Angela M Mitchell; Aimon A Alkanani; Kristen A McDaniel; Laura Pyle; Kathleen Waugh; Andrea K Steck; Maki Nakayama; Liping Yu; Peter A Gottlieb; Marian J Rewers; Aaron W Michels
Journal:  Proc Natl Acad Sci U S A       Date:  2021-02-09       Impact factor: 11.205

2.  The role of proteomics in assessing beta-cell dysfunction and death in type 1 diabetes.

Authors:  Ernesto S Nakayasu; Wei-Jun Qian; Carmella Evans-Molina; Raghavendra G Mirmira; Decio L Eizirik; Thomas O Metz
Journal:  Expert Rev Proteomics       Date:  2019-06-24       Impact factor: 3.940

Review 3.  Neoepitopes: a new take on beta cell autoimmunity in type 1 diabetes.

Authors:  Stuart I Mannering; Anthony R Di Carluccio; Colleen M Elso
Journal:  Diabetologia       Date:  2018-11-06       Impact factor: 10.122

4.  Modifying Enzymes Are Elicited by ER Stress, Generating Epitopes That Are Selectively Recognized by CD4+ T Cells in Patients With Type 1 Diabetes.

Authors:  Meghan L Marre; John W McGinty; I-Ting Chow; Megan E DeNicola; Noah W Beck; Sally C Kent; Alvin C Powers; Rita Bottino; David M Harlan; Carla J Greenbaum; William W Kwok; Jon D Piganelli; Eddie A James
Journal:  Diabetes       Date:  2018-04-13       Impact factor: 9.461

Review 5.  Tools to define the melanoma-associated immunopeptidome.

Authors:  Eva Bräunlein; Angela M Krackhardt
Journal:  Immunology       Date:  2017-08-28       Impact factor: 7.397

Review 6.  NIH Initiative to Improve Understanding of the Pancreas, Islet, and Autoimmunity in Type 1 Diabetes: The Human Pancreas Analysis Program (HPAP).

Authors:  Klaus H Kaestner; Alvin C Powers; Ali Naji; Mark A Atkinson
Journal:  Diabetes       Date:  2019-05-24       Impact factor: 9.461

Review 7.  Exploiting non-canonical translation to identify new targets for T cell-based cancer immunotherapy.

Authors:  Céline M Laumont; Claude Perreault
Journal:  Cell Mol Life Sci       Date:  2017-08-19       Impact factor: 9.261

8.  Bridge between type 1 diabetes in mouse and man.

Authors:  Defu Zeng
Journal:  Proc Natl Acad Sci U S A       Date:  2017-10-02       Impact factor: 11.205

9.  T-Cell Epitopes and Neo-epitopes in Type 1 Diabetes: A Comprehensive Update and Reappraisal.

Authors:  Eddie A James; Roberto Mallone; Sally C Kent; Teresa P DiLorenzo
Journal:  Diabetes       Date:  2020-07       Impact factor: 9.461

Review 10.  Autoimmunity in 2017.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2018-12       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.